Next Article in Journal / Special Issue
CRIPTO and miR-371a-3p Are Serum Biomarkers of Testicular Germ Cell Tumors and Are Detected in Seminal Plasma from Azoospermic Males
Previous Article in Journal
LRRC15 Targeting in Soft-Tissue Sarcomas: Biological and Clinical Implications
Previous Article in Special Issue
Age-Dependent Presentation and Clinical Course of 1465 Patients Aged 0 to Less than 18 Years with Ovarian or Testicular Germ Cell Tumors; Data of the MAKEI 96 Protocol Revisited in the Light of Prenatal Germ Cell Biology
 
 
Article

Evaluation of Circulating miRNA Biomarkers of Testicular Germ Cell Tumors during Therapy and Follow-up―A Copenhagen Experience

1
Department of Growth and Reproduction, Rigshospitalet, University of Copenhagen, Copenhagen 2100, Denmark
2
International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health (EDMaRC), Rigshospitalet, University of Copenhagen, Copenhagen 2100, Denmark
3
Department of Oncology, Rigshospitalet, University of Copenhagen, Copenhagen 2100, Denmark
*
Authors to whom correspondence should be addressed.
Cancers 2020, 12(3), 759; https://doi.org/10.3390/cancers12030759
Received: 30 January 2020 / Revised: 17 March 2020 / Accepted: 19 March 2020 / Published: 23 March 2020
(This article belongs to the Special Issue Germ Cell Tumors)
New microRNA-based serum biomarkers (miRNA-367-3p, -371a-3p, -372-3p, and -373-3p) have shown great potential for the detection of testicular germ cell tumors (TGCTs), but few studies have investigated the clinical utility and performance of these tests in treatment monitoring. In this study, circulating miRNA levels were measured, together with serum tumor markers alpha-fetoprotein (AFP), β-subunit of human chorionic gonadotropin (β-HCG) and lactate dehydrogenase (LDH) in 406 consecutive blood samples obtained during the treatment and follow-up of 52 TGCT patients at the Copenhagen University Hospital. After testing three different methods of RNA isolation from peripheral blood and PCR quantification in a subset of samples (n = 15), the best performing setup of targeted isolation of miRNAs inside and outside exosomes was selected to analyze all samples. At primary diagnosis, the miRNAs significantly outperformed the serum tumor markers, with a sensitivity and specificity of 78% and 100% (based on 40 patients), respectively. The picture was not as clear when patient trajectories were investigated, with both positive and negative signals for miRNAs and serum tumor markers. To establish whether measuring miRNAs adds value beyond the primary diagnosis, large prospective clinical trials comparing miRNAs and classical tumor markers during the treatment and follow-up of TGCT patients are needed. View Full-Text
Keywords: miRNA; miR-371a; AFP; HCG; testicular germ cell cancer; chemotherapy; follow-up; TGCT miRNA; miR-371a; AFP; HCG; testicular germ cell cancer; chemotherapy; follow-up; TGCT
Show Figures

Figure 1

MDPI and ACS Style

Mørup, N.; Rajpert-De Meyts, E.; Juul, A.; Daugaard, G.; Almstrup, K. Evaluation of Circulating miRNA Biomarkers of Testicular Germ Cell Tumors during Therapy and Follow-up―A Copenhagen Experience. Cancers 2020, 12, 759. https://doi.org/10.3390/cancers12030759

AMA Style

Mørup N, Rajpert-De Meyts E, Juul A, Daugaard G, Almstrup K. Evaluation of Circulating miRNA Biomarkers of Testicular Germ Cell Tumors during Therapy and Follow-up―A Copenhagen Experience. Cancers. 2020; 12(3):759. https://doi.org/10.3390/cancers12030759

Chicago/Turabian Style

Mørup, Nina, Ewa Rajpert-De Meyts, Anders Juul, Gedske Daugaard, and Kristian Almstrup. 2020. "Evaluation of Circulating miRNA Biomarkers of Testicular Germ Cell Tumors during Therapy and Follow-up―A Copenhagen Experience" Cancers 12, no. 3: 759. https://doi.org/10.3390/cancers12030759

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop